Summary
Insulin antibodies and T-cell lymphocyte cytotoxic reactivity against insulin and its related peptides were studied longitudinally in 3 groups of patients with type I diabetes mellitus (DM). Group 1 patients were those in whom the diagnosis was made within 1 week of the initiation diagnosis. They were subdivided into those receiving MC porcine (A) or MC bovine (B) insulin. Group 2 patients were those with a duration of DM for 2–6 years who were receiving either MC porcine (A) or MC bovine (B) insulins. Group 3 subjects were those who had been on conventional recrystallized insulin and then switched to MC porcine (A) or MC bovine (B) insulins for 2 weeks before the start of the study. The incidence of cytotoxic reactions and insulin antibodies were approximately 40–50% for group 1 (either 1A or 1B) at the initiation of the study. At 3-month follow up all patients in group 1B developed insulin antibodies (p<0.02) and a significant increase in the frequency of cytotoxic reactions (p<0.01). By contrast there was a decline in the frequency of cytotoxic reactions in group 1A (p<0.01 at 1 year) and the increase in insulin antibodies was non-significant. Group 2B had higher frequency in cytotoxic reactions (p<0.005) and of insulin antibodies (p<0.05) than group 2A. A significant decrease (p<0.01) in cytotoxic reactions was observed at 3 months following the switch of patients from conventional bovine insulin preparations to ‘A’ but not to ‘B’. However in both subgroups insulin antibodies persisted for at least 12 months. Cross-reactivity between antibodies to human, porcine and bovine insulins was evident in all groups. The early cellular and humoral immune phenomena were positively correlated in both group 1A and 1B suggesting their common involvement in the pathogenesis of DM.
Similar content being viewed by others
References
Baskin B. L., Rosenthal A. S.: Determinant specific suppression of antigen induced T-cell proliferation in the guinea-pig. Quantitation of suppressed antigen-specific T-cell responses as a consequence of prior exposure to antigen in complete Freund’s adjuvant—J. Immunol.124, 184–193, 1980.
Bloom S. R., Barnes A. J., Adrian T. E., Polak J. M.: Autoimmunity in diabetics induced by hormonal contaminants of insulin—Lanceti, 14–17, 1979.
Dean B. M., Walker R., Bone A. J., Baird J. D., Cooke A.: Prediabetes in the spontaneously diabetic BB/E rat: lymphocyte subpopulations in the pancreatic infiltrate and expression of MHC class II molecules in endocrine cells—Diabetologia28 464–66, 1985.
Diaz J.-L., Wilkin T.: Differences in epitope restriction of autoantibodies to native human insulin (1AA) and antibodies to heterologous insulin—Diabetes36, 66–72, 1987.
Fairchild R. S., Kyner J. L., Abdou N. I.: Specific immunoregulation abnormality in insulin-dependent diabetes mellitus—J. Lab. clin. Med.99, 1975–78 1982.
Gepts W.: Pathology of IDDM in man. In:Mngola E. N. (Ed.): Diabetes, 1982. Excerpta Medica, Amsterdam—Oxford—Princeton, 1983; pp 99–107.
Iavicoli M., Pozzilli P., Di Mario U.: Increased lymphocyte transformation by insulin induced hypoglycaemia in normal subjects—J. clin. Lab. Immunol.1, 351–353, 1979.
Ionescu-Tîrgoviste C., Mincu I., Simionescu L., Cheta D., Mirondon Z., Sântu E., Popa E., Bîrnea A.: Disappearance rate of insulin antibodies after discontinuing insulin treatment in 42 Type 2 (non-insulin-dependent) diabetic patients—Diabetologia27, 592–5, 1984.
Kaplan D. R., Colca J. R., McDaniel M. L.: Insulin as a surface marker on isolated cells from rat pancreatic islets—J. Cell Biol.97, 433–457, 1983.
Kontiainen S.: Human insulin specific suppressor factors. Induction characteristics and comparison of murine factors—Clin. exp. Immunol.47, 715–724, 1982.
Kuhnau J., Rudiger H., Goetz K.: Circulating insulin antibodies during therapy with highly purified neutrally buffered insulins including desphe insulins—Exp. clin. Endocrinol.83, 161–7, 1984.
Kurtz A. B., Gray R. S., Markanday S., Nabarro J. D. N.: Circulating IgG antibody to protamine in patients treated with protamine-insulins—Diabetologia25, 322–4, 1983.
Kurtz A. B., Mathews J. A., Mustaffa B. E., Daggett P. K., Nabarro J. D. N.: Decrease of antibodies to insulin, proinsulin and contaminating hormones after changing treatment from conventional beef to purified pork insulin—Diabetologia18, 147–150, 1980.
MacCuish A. C., Urbaniak S. J., Campbell C. J., Duncan L. J. P., Irvine W. J.: Phytohaemagglutinin transformation and circulating lymphocyte subpopulations in insulin dependent diabetic patients—Diabetes23, 708–710, 1974.
Mann D. L., Mendell N., Kahn C. R., Johnson A. H., Rosenthal A. S.:In vitro lymphocyte proliferation response to therapeutic insulin components. Evidence for genetic control by the human major histocompatibility complex—J. clin. Invest.72, 1130–1138 1983.
Palmer J. P., Asplin C. M., Clemens P., Lyen K., Tatpati O., Raghu P. K., Paquette T. L.: Insulin antibodies in insulin-dependent diabetics before insulin treatment— Science222, 1337–1339, 1983.
Peacock I., Taylor A., Tattersall R. B., Douglas C. A., Reeves W. G.: Effects of new insulins on insulin and C-peptide antibodies, insulin dose and diabetic control—Lanceti, 149–152, 1983.
Reeves W. G., Kelly U.: Insulin antibodies induced by bovine insulin therapy—Clin. exp. Immunol.50, 163–170, 1985.
Richens E. R., Luqman W., Groves R. W.: Reduced insulin binding by lymphoblastoid cell lines homozygous for HLA-DR3 and-DR4 genotypes. In:Jaworski M. A., Molnar G. D., Rajotte R. V., Singh B. (Eds): Immunology of diabetes. International Congress Series No. 717. Elsevier Science Publishers, Amsterdam, 1987; pp 263–267.
Richens E. R., Seward E. R., Groves R. W.: Cellular cytotoxicity to membrane-associated in an autologous system—Acta diabetol. lat.22, 55–62, 1985.
Richens E. R., Seward M. E., Luqman W. A., Hartog M.: The human cellular immune response to insulin: a study in unexposed control subjects and type I diabetic patients on acute and chronic treatment—J. clin. Lab. Immunol.11, 135–141, 1983.
Schernthaner G., Borkenstein M., Fink M., Mayr W. R., Menzel J., Schober E.: Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR typed insulin-dependent diabetic individuals. In:Karam J. H., Etzwiler D. D. (Eds): International Symposium on Human Insulin. Diabetes Care6 (Suppl. 1), 43–8, 1983.
Thomas J. W., Virta V. J., Nell L. J.: Heterogeneity and specificity of human anti-insulin antibodies determined by isoelectric focusing—J. Immunol.134, 1048–52, 1985.
Wilkin T., Armitage M., Casey C., Pyke D. A., Hoskins P. J., Rodier M., Diaz J. L., Leslie R. D. G.: Value of insulin autoantibodies as serum markers for insulin-dependent diabetes mellitus—Lanceti, 430–483, 1985.
Wilkin T. J., Nicholson S.: Autoantibodies against human insulin—Brit. med. J.288, 249–352, 1984.
Wilson R. M., Douglas C. A., Tattersall R. B., Reeves G. W.: Immunogenicity of highly purified bovine insulin: a comparison with conventional bovine and highly purified human insulins—Diabetologia28, 667–70, 1985.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Richens, E.R., Seward, M.E., Hartog, M. et al. A longitudinal study of insulin antibodies and anti-insulin cytotoxicity in type I diabetes mellitus. Acta diabet. lat 24, 271–282 (1987). https://doi.org/10.1007/BF02742958
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02742958